Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nu Holdings Ltd (NU) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

NU Holdings Ltd. (NU) trades at $13.76, up 0.66% on the day, with a bullish technical signal from moving averages and strong fundamental growth. Revenue grew to $10.63B in 2025 with net income of $2.87B, and the company recently secured authorization for its Mexican banking operations, expanding its Latin American footprint. Analyst consensus is a Buy with a $14.98 price target, though recent quarterly EPS results have missed expectations.

The outlook for NU remains positive due to robust revenue growth and expansion potential, but risks include currency headwinds and competitive pressures. The stock's current valuation at a P/E of 21.22 and P/S of 5.67 reflects its growth trajectory, yet investors should monitor execution risks in new markets and credit portfolio performance.